Clinical Trial Detail

NCT ID NCT02581982
Title Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Comprehensive Cancer Center of Wake Forest University
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Pembrolizumab

Paclitaxel

Age Groups: adult

No variant requirements are available.